{"DataElement":{"publicId":"6032917","version":"1","preferredName":"Gleason Original Assessment Score","preferredDefinition":"Numeric representation of the original Gleason score.","longName":"ORIG_GLEASON_SCR","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"6032845","version":"1","preferredName":"Gleason Score for Prostate Cancer Original Assessment","preferredDefinition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable._Preceding all others in time or being as first made or performed._The final result of a determination of the value, significance, or extent of.","longName":"2547908v1.0:6032843v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"2547908","version":"1","preferredName":"Gleason Score for Prostate Cancer","preferredDefinition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.","longName":"C28084","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score for Prostate Cancer","conceptCode":"C28084","definition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"23681B08-081C-19C0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-11-29","modifiedBy":"SBREXT","dateModified":"2017-08-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6032843","version":"1","preferredName":"Original Assessment","preferredDefinition":"Preceding all others in time or being as first made or performed.:The final result of a determination of the value, significance, or extent of.","longName":"C25604:C25217","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Original","conceptCode":"C25604","definition":"Preceding all others in time or being as first made or performed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assessment","conceptCode":"C25217","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F038289-62B2-3955-E053-F662850A5E90","latestVersionIndicator":"Yes","beginDate":"2017-11-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-11-27","modifiedBy":"ONEDATA","dateModified":"2017-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F038289-62C3-3955-E053-F662850A5E90","latestVersionIndicator":"Yes","beginDate":"2017-11-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-11-27","modifiedBy":"COOPERM","dateModified":"2017-12-04","changeDescription":"Created for Dr. Turkbey P173316 request 11.21.17 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2015237","version":"4","preferredName":"Gleason Score","preferredDefinition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable._A number or range of numeric values measuring performance, function, quality, or ability.","longName":"2015237v4.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"NUMBER","minLength":"1","maxLength":"2","minValue":null,"maxValue":null,"decimalPlace":"0","PermissibleValues":[{"value":"10","valueDescription":"Gleason Score 10 ","ValueMeaning":{"publicId":"5918377","version":"1","preferredName":"Gleason Score 10 ","longName":"5918377","preferredDefinition":"A Gleason score that indicates a highly aggressive prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score 10","conceptCode":"C28094","definition":"A Gleason score that indicates a highly aggressive prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5641149B-B351-5B37-E053-F662850A95C2","latestVersionIndicator":"Yes","beginDate":"2017-08-08","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2017-08-08","modifiedBy":"TAYLORT","dateModified":"2017-08-08","changeDescription":"Updated to correct concept. mc 2/13/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5641149B-B36B-5B37-E053-F662850A95C2","beginDate":"2002-02-11","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2017-08-08","modifiedBy":"ONEDATA","dateModified":"2017-08-08","deletedIndicator":"No"},{"value":"3","valueDescription":"Gleason Score 3 ","ValueMeaning":{"publicId":"5918384","version":"1","preferredName":"Gleason Score 3 ","longName":"5918384","preferredDefinition":"A Gleason score that is exceptionally assigned and indicates a low-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score 3","conceptCode":"C28096","definition":"A Gleason score that is exceptionally assigned and indicates a low-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"56435516-4DBB-1BCA-E053-F662850AE97A","latestVersionIndicator":"Yes","beginDate":"2017-08-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"56435516-4DD4-1BCA-E053-F662850AE97A","beginDate":"2002-02-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"ONEDATA","dateModified":"2017-08-08","deletedIndicator":"No"},{"value":"9","valueDescription":"Gleason Score 9 ","ValueMeaning":{"publicId":"5918382","version":"1","preferredName":"Gleason Score 9 ","longName":"5918382","preferredDefinition":"A Gleason score that indicates a high-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score 9","conceptCode":"C28093","definition":"A Gleason score that indicates a high-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"56435516-4D6E-1BCA-E053-F662850AE97A","latestVersionIndicator":"Yes","beginDate":"2017-08-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"TAYLORT","dateModified":"2017-08-08","changeDescription":"Updated to correct concept. mc 2/13/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"56435516-4D88-1BCA-E053-F662850AE97A","beginDate":"2002-02-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"ONEDATA","dateModified":"2017-08-08","deletedIndicator":"No"},{"value":"4","valueDescription":"Gleason Score 4","ValueMeaning":{"publicId":"5918385","version":"1","preferredName":"Gleason Score 4","longName":"5918385","preferredDefinition":"A Gleason score that is relatively uncommon and indicates a low-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score 4","conceptCode":"C28097","definition":"A Gleason score that is relatively uncommon and indicates a low-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"56435516-4DE1-1BCA-E053-F662850AE97A","latestVersionIndicator":"Yes","beginDate":"2017-08-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"TAYLORT","dateModified":"2017-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"56435516-4DFA-1BCA-E053-F662850AE97A","beginDate":"2002-02-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"ONEDATA","dateModified":"2017-08-08","deletedIndicator":"No"},{"value":"5","valueDescription":"Gleason Score 5 ","ValueMeaning":{"publicId":"5918386","version":"1","preferredName":"Gleason Score 5 ","longName":"5918386","preferredDefinition":"An exceptionally uncommon Gleason score that indicates a less aggressive prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score 5","conceptCode":"C28098","definition":"An exceptionally uncommon Gleason score that indicates a less aggressive prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"56435516-4E07-1BCA-E053-F662850AE97A","latestVersionIndicator":"Yes","beginDate":"2017-08-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"TAYLORT","dateModified":"2017-08-08","changeDescription":"Updated to correct concept. mc 2/13/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"56435516-4E21-1BCA-E053-F662850AE97A","beginDate":"2002-02-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"ONEDATA","dateModified":"2017-08-08","deletedIndicator":"No"},{"value":"6","valueDescription":"Gleason Score 6 ","ValueMeaning":{"publicId":"5918387","version":"1","preferredName":"Gleason Score 6 ","longName":"5918387","preferredDefinition":"A Gleason score that indicates a low-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score 6","conceptCode":"C28090","definition":"A Gleason score that indicates a low-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"56435516-4E2E-1BCA-E053-F662850AE97A","latestVersionIndicator":"Yes","beginDate":"2017-08-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"TAYLORT","dateModified":"2017-08-08","changeDescription":"Updated to correct concept. mc 2/13/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"56435516-4E48-1BCA-E053-F662850AE97A","beginDate":"2002-02-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"ONEDATA","dateModified":"2017-08-08","deletedIndicator":"No"},{"value":"7","valueDescription":"Gleason Score 7 ","ValueMeaning":{"publicId":"5918388","version":"1","preferredName":"Gleason Score 7 ","longName":"5918388","preferredDefinition":"A Gleason score that indicates an intermediate-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score 7","conceptCode":"C28091","definition":"A Gleason score that indicates an intermediate-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"56435516-4E55-1BCA-E053-F662850AE97A","latestVersionIndicator":"Yes","beginDate":"2017-08-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"TAYLORT","dateModified":"2017-08-08","changeDescription":"Updated to correct concept. mc 2/13/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"56435516-4E6F-1BCA-E053-F662850AE97A","beginDate":"2002-02-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"ONEDATA","dateModified":"2017-08-08","deletedIndicator":"No"},{"value":"8","valueDescription":"Gleason Score 8 ","ValueMeaning":{"publicId":"5918389","version":"1","preferredName":"Gleason Score 8 ","longName":"5918389","preferredDefinition":"A Gleason score that indicates a histologically aggressive prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score 8","conceptCode":"C28092","definition":"A Gleason score that indicates a histologically aggressive prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"56435516-4E7C-1BCA-E053-F662850AE97A","latestVersionIndicator":"Yes","beginDate":"2017-08-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"TAYLORT","dateModified":"2017-08-08","changeDescription":"Updated to correct concept. mc 2/13/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"56435516-4E96-1BCA-E053-F662850AE97A","beginDate":"2002-02-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"ONEDATA","dateModified":"2017-08-08","deletedIndicator":"No"},{"value":"2","valueDescription":"Gleason Score 2","ValueMeaning":{"publicId":"5918390","version":"1","preferredName":"Gleason Score 2","longName":"5918390","preferredDefinition":"A low Gleason score that is exceptionally uncommon and indicates a low-grade, non-aggressive prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score 2","conceptCode":"C28095","definition":"A low Gleason score that is exceptionally uncommon and indicates a low-grade, non-aggressive prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"564361CC-31D1-28D1-E053-F662850A64B0","latestVersionIndicator":"Yes","beginDate":"2017-08-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"ONEDATA","dateModified":"2017-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"564361CC-31EA-28D1-E053-F662850A64B0","beginDate":"2002-02-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"ONEDATA","dateModified":"2017-08-08","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5918402","version":"1","preferredName":"Gleason Score for Prostate Cancer Score","preferredDefinition":"A system of grading prostate cancer tissue based on how it looks under a microscope. Gleason scores range from 2 to 10 and indicate how likely it is that a tumor will spread. A low Gleason score means the cancer tissue is similar to normal prostate tissue and the tumor is less likely to spread; a high Gleason score means the cancer tissue is very different from normal and the tumor is more likely to spread.:A number or range of numeric values measuring performance, function, quality, or ability.","longName":"C28084:C25338","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score for Prostate Cancer","conceptCode":"C28084","definition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Score","conceptCode":"C25338","definition":"A number or range of numeric values measuring performance, function, quality, or ability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"56435B98-052D-2101-E053-F662850A10FF","latestVersionIndicator":"Yes","beginDate":"2017-08-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"ONEDATA","dateModified":"2017-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"56416639-FBC6-1D78-E053-F662850AD6D9","latestVersionIndicator":"Yes","beginDate":"2004-05-17","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2017-08-08","modifiedBy":"COOPERM","dateModified":"2017-12-04","changeDescription":"8/23/17 tt released DN VD. 8/8/17 tt VD versioned for change to rep term, qualifier, def, long name; added CSI and reg status, transferred context per Round 5 finalization task.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[{"name":"DCP","type":"USED_BY","context":"DCP"}],"ReferenceDocuments":[{"name":"Original Gleason score","type":"Preferred Question Text","description":"Original Gleason score","url":null,"context":"CCR"},{"name":"DCP CRF Text","type":"Alternate Question Text","description":"Prestudy Gleason Score","url":null,"context":"DCP"}],"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F0B665C-55C5-23DE-E053-F662850AA0D1","latestVersionIndicator":"Yes","beginDate":"2017-11-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-11-28","modifiedBy":"ZHANGWE","dateModified":"2018-09-28","changeDescription":"Created for Dr. Turkbey P173316 request 11.21.17 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}